Cargando…

A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet

Many commercially available wound products focus on improving one stage of the wound healing cascade. While this targeted approach works for specific wounds, there is a need for products that can reliably and comprehensively progress a wound through multiple stages. This preliminary in vitro study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Isaac, Conti, Tricia, Bionda, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503338/
https://www.ncbi.nlm.nih.gov/pubmed/36142583
http://dx.doi.org/10.3390/ijms231810670
_version_ 1784795938256060416
author Rodriguez, Isaac
Conti, Tricia
Bionda, Nina
author_facet Rodriguez, Isaac
Conti, Tricia
Bionda, Nina
author_sort Rodriguez, Isaac
collection PubMed
description Many commercially available wound products focus on improving one stage of the wound healing cascade. While this targeted approach works for specific wounds, there is a need for products that can reliably and comprehensively progress a wound through multiple stages. This preliminary in vitro study was performed to directly compare the inflammatory reduction and growth factor production effects of three commercially available wound care products: a collagen sheet (COL), a Manuka Honey Calcium Alginate sheet (MH), and a novel bioengineered sheet comprised of a collagen derivative (gelatin), Manuka honey, and hydroxyapatite (BCMH). Macrophages and human dermal fibroblasts were directly seeded on all three commercial products, and supernatants were analyzed for inflammatory markers and growth factors, respectively. Comparing the MMP-9/TIMP-1 ratio, BCMH resulted in 11× lower levels of this inflammation biomarker compared to COL, and 3× lower levels compared to MH. Both the COL and BCMH products created an environment conducive to expression and release of relevant growth factors, while the MH product showed the lowest levels of growth factor expression of all three commercially available products tested. The favorable 11× lower MMP-9/TIMP-1 ratio observed with the BCMH product compared to the COL product suggests that the BCMH products provided a superior comprehensive approach to healthy progression of the wounds by providing an additional benefit of reducing the inflammatory response in vitro.
format Online
Article
Text
id pubmed-9503338
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95033382022-09-24 A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet Rodriguez, Isaac Conti, Tricia Bionda, Nina Int J Mol Sci Communication Many commercially available wound products focus on improving one stage of the wound healing cascade. While this targeted approach works for specific wounds, there is a need for products that can reliably and comprehensively progress a wound through multiple stages. This preliminary in vitro study was performed to directly compare the inflammatory reduction and growth factor production effects of three commercially available wound care products: a collagen sheet (COL), a Manuka Honey Calcium Alginate sheet (MH), and a novel bioengineered sheet comprised of a collagen derivative (gelatin), Manuka honey, and hydroxyapatite (BCMH). Macrophages and human dermal fibroblasts were directly seeded on all three commercial products, and supernatants were analyzed for inflammatory markers and growth factors, respectively. Comparing the MMP-9/TIMP-1 ratio, BCMH resulted in 11× lower levels of this inflammation biomarker compared to COL, and 3× lower levels compared to MH. Both the COL and BCMH products created an environment conducive to expression and release of relevant growth factors, while the MH product showed the lowest levels of growth factor expression of all three commercially available products tested. The favorable 11× lower MMP-9/TIMP-1 ratio observed with the BCMH product compared to the COL product suggests that the BCMH products provided a superior comprehensive approach to healthy progression of the wounds by providing an additional benefit of reducing the inflammatory response in vitro. MDPI 2022-09-14 /pmc/articles/PMC9503338/ /pubmed/36142583 http://dx.doi.org/10.3390/ijms231810670 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Rodriguez, Isaac
Conti, Tricia
Bionda, Nina
A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
title A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
title_full A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
title_fullStr A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
title_full_unstemmed A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
title_short A Preliminary Direct Comparison of the Inflammatory Reduction and Growth Factor Production Capabilities of Three Commercially Available Wound Products: Collagen Sheet, Manuka Honey Sheet, and a Novel Bioengineered Collagen Derivative + Manuka Honey + Hydroxyapatite Sheet
title_sort preliminary direct comparison of the inflammatory reduction and growth factor production capabilities of three commercially available wound products: collagen sheet, manuka honey sheet, and a novel bioengineered collagen derivative + manuka honey + hydroxyapatite sheet
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503338/
https://www.ncbi.nlm.nih.gov/pubmed/36142583
http://dx.doi.org/10.3390/ijms231810670
work_keys_str_mv AT rodriguezisaac apreliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet
AT contitricia apreliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet
AT biondanina apreliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet
AT rodriguezisaac preliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet
AT contitricia preliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet
AT biondanina preliminarydirectcomparisonoftheinflammatoryreductionandgrowthfactorproductioncapabilitiesofthreecommerciallyavailablewoundproductscollagensheetmanukahoneysheetandanovelbioengineeredcollagenderivativemanukahoneyhydroxyapatitesheet